Celgene Corporation Company Profile (NASDAQ:CELG)

About Celgene Corporation (NASDAQ:CELG)

Celgene Corporation logoCelgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CELG
  • CUSIP: 15102010
  • Web: www.celgene.com
Capitalization:
  • Market Cap: $112.57245 billion
  • Outstanding Shares: 782,350,000
Average Prices:
  • 50 Day Moving Avg: $135.45
  • 200 Day Moving Avg: $127.81
  • 52 Week Range: $96.93 - $144.19
P/E:
  • Trailing P/E Ratio: 44.89
  • Foreward P/E Ratio: 17.11
  • P/E Growth: 0.91
Sales & Book Value:
  • Annual Revenue: $12.19 billion
  • Price / Sales: 9.23
  • Book Value: $10.80 per share
  • Price / Book: 13.32
Profitability:
  • EBIDTA: $4.83 billion
  • Net Margins: 21.35%
  • Return on Equity: 68.51%
  • Return on Assets: 17.04%
Debt:
  • Debt-to-Equity Ratio: 1.63%
  • Current Ratio: 4.05%
  • Quick Ratio: 3.89%
Misc:
  • Average Volume: 3.73 million shs.
  • Beta: 1.89
  • Short Ratio: 2.63
 

Frequently Asked Questions for Celgene Corporation (NASDAQ:CELG)

What is Celgene Corporation's stock symbol?

Celgene Corporation trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene Corporation's stock split? How did Celgene Corporation's stock split work?

Celgene Corporation shares split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were payable to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene Corporation stock prior to the split would have 200 shares after the split.

How were Celgene Corporation's earnings last quarter?

Celgene Corporation (NASDAQ:CELG) issued its quarterly earnings results on Thursday, July, 27th. The company reported $1.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business's revenue was up 18.7% on a year-over-year basis. During the same period last year, the company earned $1.44 earnings per share. View Celgene Corporation's Earnings History.

When will Celgene Corporation make its next earnings announcement?

Celgene Corporation is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Celgene Corporation.

What guidance has Celgene Corporation issued on next quarter's earnings?

Celgene Corporation issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $7.25-7.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.29. The company issued revenue guidance of $13.0-13.4 billion, compared to the consensus revenue estimate of $13.19 billion.

Where is Celgene Corporation's stock going? Where will Celgene Corporation's stock price be in 2017?

26 analysts have issued 1-year price objectives for Celgene Corporation's shares. Their predictions range from $98.00 to $176.00. On average, they anticipate Celgene Corporation's stock price to reach $149.86 in the next year. View Analyst Ratings for Celgene Corporation.

What are analysts saying about Celgene Corporation stock?

Here are some recent quotes from research analysts about Celgene Corporation stock:

  • 1. Cann analysts commented, "Celgene announced that Idhifa (enasidenib/AG-221) was granted approval from FDA for the treatment of adult patients with relapsed or refractory AML with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test. It was reported that FDA approval was based on the clinical data from an open-label, single-arm, multicenter, two-cohort clinical trial of adult patients with relapsed or refractory AML with an IDH2 mutation (Study AG221-C-001, NCT01915498). Idhifa was approved concurrently with the Abbott RealTime IDH2 companion diagnostic test, which is FDA-approved as an aid in identifying AML patients for treatment with Idhifa." (8/1/2017)
  • 2. According to Zacks Investment Research, "Celgene’s key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration. Celgene continues to progress with its label expansion efforts and pipeline development. Revlimid was approved as a single agent for maintenance therapy in adult patients with NDMM following ASCT both in the U.S. and EU. Celgene’s NDA for Idhifa for relapsed and/or refractory acute myeloid leukemia was granted Priority Review with a PDUFA action date of Aug 30, 2017. Label expansion of drugs would boost revenues significantly. Moreover, shares of Celgene have outperformed the industry in the past one year. However, Celgene is highly dependent on Revlimid. Otezla sales in the first quarter were impacted by managed care dynamics that drove lower total marketplace prescriptions for psoriasis therapies although the pressure should ease as the year goes." (7/19/2017)
  • 3. Cantor Fitzgerald analysts commented, "Acquisition of worldwide Rights to BeiGene,s (NASDAQ: BGNE, NC) excluding Asia, PD-1 inhibitor for solid tumors, BGB-A317, enhances CELG’s oncology portfolio and augments its immuno-oncology efforts." (7/6/2017)

Who are some of Celgene Corporation's key competitors?

Who are Celgene Corporation's key executives?

Celgene Corporation's management team includes the folowing people:

  • Robert J. Hugin, Executive Chairman of the Board
  • Scott A. Smith, President, Chief Operating Officer
  • Mark J. Alles, Chief Executive Officer, Director
  • Peter N. Kellogg, Chief Financial Officer, Executive Vice President
  • Terrie Curran, President, Global Inflammation & Immunology Franchise
  • Michael F. Pehl, President, Hematology & Oncology
  • Rupert J. Vessey, President - Research and Early Development
  • Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary
  • Michael D. Casey, Lead Independent Director
  • Michael W. Bonney, Director

Who owns Celgene Corporation stock?

Celgene Corporation's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.25%), Vanguard Group Inc. (6.84%), State Street Corp (4.14%), Jennison Associates LLC (1.71%), FMR LLC (1.61%) and Franklin Resources Inc. (1.42%). Company insiders that own Celgene Corporation stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin and Rupert Vessey. View Institutional Ownership Trends for Celgene Corporation.

Who sold Celgene Corporation stock? Who is selling Celgene Corporation stock?

Celgene Corporation's stock was sold by a variety of institutional investors in the last quarter, including Orbis Allan Gray Ltd, Old Mutual Global Investors UK Ltd., Winslow Capital Management LLC, Jackson Square Partners LLC, Bank of New York Mellon Corp, Geneva Advisors LLC, APG Asset Management N.V. and Macquarie Group Ltd.. Company insiders that have sold Celgene Corporation stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Robert J Hugin and Rupert Vessey. View Insider Buying and Selling for Celgene Corporation.

Who bought Celgene Corporation stock? Who is buying Celgene Corporation stock?

Celgene Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, BlackRock Inc., Oaktop Capital Management II L.P., Arrowstreet Capital Limited Partnership, Vanguard Group Inc., Harbour Capital Advisors LLC, Renaissance Technologies LLC and UBS Asset Management Americas Inc.. Company insiders that have bought Celgene Corporation stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene Corporation.

How do I buy Celgene Corporation stock?

Shares of Celgene Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene Corporation's stock price today?

One share of Celgene Corporation stock can currently be purchased for approximately $143.89.


MarketBeat Community Rating for Celgene Corporation (NASDAQ CELG)
Community Ranking:  4.0 out of 5 (star star star star)
Outperform Votes:  1,573 (Vote Outperform)
Underperform Votes:  400 (Vote Underperform)
Total Votes:  1,973
MarketBeat's community ratings are surveys of what our community members think about Celgene Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Celgene Corporation (NASDAQ:CELG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 20 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.81)
Consensus Price Target: $149.86 (4.15% upside)

Analysts' Ratings History for Celgene Corporation (NASDAQ:CELG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/21/2017Robert W. BairdReiterated RatingBuy$162.00LowView Rating Details
9/15/2017Jefferies Group LLCReiterated RatingBuy$160.00LowView Rating Details
9/15/2017MizuhoBoost Price TargetBuy -> Buy$134.00 -> $158.00MediumView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageTop Pick -> Top Pick$176.00HighView Rating Details
9/13/2017Bank of America CorporationReiterated RatingBuyLowView Rating Details
9/12/2017Cowen and CompanyReiterated RatingBuy$150.00LowView Rating Details
9/5/2017BTIG ResearchReiterated RatingNeutralLowView Rating Details
8/28/2017Cantor FitzgeraldReiterated RatingBuyLowView Rating Details
8/9/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$175.00MediumView Rating Details
8/1/2017CannReiterated RatingBuy$175.00LowView Rating Details
7/31/2017ArgusUpgradeHold -> Buy$96.93 -> $160.00LowView Rating Details
7/28/2017Barclays PLCReiterated RatingHold$135.00LowView Rating Details
7/28/2017BMO Capital MarketsReiterated RatingOutperform$152.00 -> $160.00LowView Rating Details
7/28/2017Leerink SwannReiterated RatingOutperform$150.00 -> $160.00LowView Rating Details
7/27/2017Canaccord GenuitySet Price TargetBuy$156.00LowView Rating Details
7/28/2017Stifel NicolausInitiated CoverageBuy$155.00LowView Rating Details
7/14/2017SunTrust Banks, Inc.Reiterated RatingBuy$150.00LowView Rating Details
7/6/2017Credit Suisse GroupSet Price TargetBuy$148.00LowView Rating Details
6/26/2017William BlairReiterated RatingOutperformLowView Rating Details
5/24/2017J P Morgan Chase & CoReiterated RatingBuyLowView Rating Details
5/17/2017Goldman Sachs Group, Inc. (The)Reiterated RatingSell$93.00 -> $98.00LowView Rating Details
1/27/2017Morgan StanleyLower Price TargetEqual Weight$120.00 -> $117.00N/AView Rating Details
1/8/2017Evercore ISIReiterated RatingBuy$135.00N/AView Rating Details
11/9/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
10/18/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
9/29/2016Citigroup Inc.Boost Price TargetBuy$124.00 -> $127.00N/AView Rating Details
7/6/2016JMP SecuritiesReiterated RatingBuy$152.00N/AView Rating Details
4/28/2016Raymond James Financial, Inc.Reiterated RatingBuyN/AView Rating Details
1/22/2016Wells Fargo & CompanyReiterated RatingOutperformN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral -> NeutralN/AView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for Celgene Corporation (NASDAQ:CELG)
Earnings by Quarter for Celgene Corporation (NASDAQ:CELG)
Earnings History by Quarter for Celgene Corporation (NASDAQ CELG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$1.89N/AView Earnings Details
7/27/20176/30/2017$1.61$1.82$3.23 billion$3.27 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.47$1.68$3.04 billion$2.96 billionViewN/AView Earnings Details
1/26/2017Q416$1.59$1.61$3.03 billion$2.98 billionViewN/AView Earnings Details
10/27/2016Q316$1.31$1.58$2.84 billion$2.98 billionViewListenView Earnings Details
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.09$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$0.93$0.95$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.88$0.91$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.82$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.77$0.80$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celgene Corporation (NASDAQ:CELG)
2017 EPS Consensus Estimate: $6.60
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.44$1.46$1.45
Q2 20173$1.61$1.68$1.64
Q3 20173$1.68$1.77$1.72
Q4 20173$1.72$1.84$1.78
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celgene Corporation (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Celgene Corporation (NASDAQ:CELG)
Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 79.33%
Insider Trades by Quarter for Celgene Corporation (NASDAQ:CELG)
Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)
Insider Trades by Quarter for Celgene Corporation (NASDAQ:CELG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/12/2017Gilla KaplanDirectorSell9,250$141.56$1,309,430.00View SEC Filing  
9/5/2017Michael D CaseyDirectorSell9,250$139.03$1,286,027.50View SEC Filing  
8/10/2017Ernest MarioDirectorSell18,506$130.52$2,415,403.12View SEC Filing  
8/2/2017Gilla KaplanDirectorSell7,500$134.52$1,008,900.00View SEC Filing  
6/26/2017James J LoughlinDirectorSell18,500$133.57$2,471,045.00View SEC Filing  
6/22/2017Michael A FriedmanDirectorSell10,000$132.50$1,325,000.00View SEC Filing  
6/22/2017Robert J HuginInsiderSell175,970$134.14$23,604,615.80View SEC Filing  
6/21/2017Michael D CaseyDirectorSell9,250$133.05$1,230,712.50View SEC Filing  
6/19/2017Michael D. CaseyDirectorSell9,250$125.59$1,161,707.50View SEC Filing  
6/15/2017Rupert VesseyInsiderSell4,785$120.18$575,061.30View SEC Filing  
5/1/2017James J LoughlinDirectorSell9,250$124.00$1,147,000.00View SEC Filing  
3/30/2017Gilla KaplanDirectorSell14,033$123.83$1,737,706.39View SEC Filing  
3/1/2017Rupert VesseyInsiderSell4,000$124.42$497,680.00View SEC Filing  
11/9/2016Michael A FriedmanDirectorSell18,600$116.10$2,159,460.00View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/3/2016Michael A FriedmanDirectorSell56,116$103.66$5,816,984.56View SEC Filing  
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.00View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.40View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.00View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.00View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.00View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.28View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.00View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.00View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.68View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.00View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.16View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.78View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.00View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.78View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Celgene Corporation (NASDAQ:CELG)
Latest Headlines for Celgene Corporation (NASDAQ:CELG)
Source:
DateHeadline
prnewswire.com logoHealth2047 and Celgene to Enhance Data Liquidity in Healthcare - PR Newswire (press release)
www.prnewswire.com - September 26 at 8:38 AM
nasdaq.com logoArdsley Advisory Partners Buys Alexion Pharmaceuticals Inc, New Residential Investment Corp, ...
www.nasdaq.com - September 22 at 4:04 PM
finance.yahoo.com logoJuno Tenders $250M Follow-on Public Offering of Common Stock
finance.yahoo.com - September 22 at 4:04 PM
finance.yahoo.com logoBetter Buy: Celgene Corporation vs. Merck & Co., Inc.
finance.yahoo.com - September 22 at 10:13 AM
americanbankingnews.com logoRobert W. Baird Reiterates Buy Rating for Celgene Corporation (CELG)
www.americanbankingnews.com - September 21 at 9:32 PM
reuters.com logoBRIEF-Acceleron Pharma says entered into an agreement with Celgene Corp - Reuters
www.reuters.com - September 20 at 5:50 PM
seekingalpha.com logoAcceleron tweaks Celgene agreement, to develop sotatercept for PAH - Seeking Alpha
seekingalpha.com - September 20 at 5:50 PM
finance.yahoo.com logo3 Stocks That Put Coca-Cola's Returns to Shame
finance.yahoo.com - September 20 at 5:50 PM
americanbankingnews.com logoLeerink Swann Analysts Raise Earnings Estimates for Celgene Corporation (CELG)
www.americanbankingnews.com - September 20 at 1:34 PM
reuters.com logoBRIEF-Acceleron Pharma says entered into an agreement with Celgene Corp
www.reuters.com - September 19 at 5:08 PM
americanbankingnews.com logoFY2018 Earnings Estimate for Celgene Corporation (CELG) Issued By Leerink Swann
www.americanbankingnews.com - September 19 at 10:38 AM
finance.yahoo.com logoRoche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA
finance.yahoo.com - September 18 at 8:39 PM
nasdaq.com logoNotable ETF Outflow Detected - ITOT, DWDP, CELG, HON
www.nasdaq.com - September 18 at 3:36 PM
finance.yahoo.com logoGilead Sciences: Is The Kite Deal Too Little, Too Late?
finance.yahoo.com - September 18 at 3:36 PM
finance.yahoo.com logoWhat Analysts Recommend for Novartis in September 2017
finance.yahoo.com - September 18 at 3:36 PM
finance.yahoo.com logoDon't Make This Huge Mistake With Celgene
finance.yahoo.com - September 17 at 4:45 PM
fool.com logoDon't Make This Huge Mistake With Celgene
www.fool.com - September 17 at 9:22 AM
americanbankingnews.com logoCelgene Corporation (CELG) Earns Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - September 16 at 4:04 PM
finance.yahoo.com logoTraders give their award-winning stock picks ahead of thi...
finance.yahoo.com - September 15 at 10:32 PM
americanbankingnews.com logoCelgene Corporation (CELG) Price Target Increased to $158.00 by Analysts at Mizuho
www.americanbankingnews.com - September 15 at 7:28 AM
americanbankingnews.com logoRoyal Bank Of Canada Initiates Coverage on Celgene Corporation (CELG)
www.americanbankingnews.com - September 14 at 11:06 PM
americanbankingnews.com logoGilla Kaplan Sells 9,250 Shares of Celgene Corporation (CELG) Stock
www.americanbankingnews.com - September 14 at 10:52 PM
nasdaq.com logoNoteworthy Thursday Option Activity: EQT, ESRX, CELG
www.nasdaq.com - September 14 at 5:46 PM
finance.yahoo.com logoRBC Launches Biotech Sector Coverage Amid 'An Innovation Revolution'
finance.yahoo.com - September 14 at 5:46 PM
americanbankingnews.com logoBank of America Corporation Reaffirms Buy Rating for Celgene Corporation (CELG)
www.americanbankingnews.com - September 13 at 3:34 PM
americanbankingnews.com logoCelgene Corporation (CELG) Earns "Buy" Rating from Cowen and Company
www.americanbankingnews.com - September 12 at 7:36 PM
americanbankingnews.com logoCelgene Corporation (CELG) Expected to Announce Quarterly Sales of $3.44 Billion
www.americanbankingnews.com - September 12 at 8:52 AM
fool.com logo3 Growth Stocks to Hold for 50 Years
www.fool.com - September 12 at 8:18 AM
seekingalpha.com logoCelgene Offers High Growth At An Inexpensive Price - Seeking Alpha
seekingalpha.com - September 11 at 5:44 PM
americanbankingnews.com logoCelgene Corporation (CELG) Downgraded by Vetr Inc. to Hold
www.americanbankingnews.com - September 10 at 3:58 PM
americanbankingnews.com logoCelgene Corporation (CELG) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 9 at 12:58 PM
businesswire.com logoData Presented at ESMO 2017 Further Evaluate Role of ABRAXANE ... - Business Wire (press release)
www.businesswire.com - September 9 at 3:31 AM
marketwatch.com logoCelgene shares drop 1% on news that FDA has placed six trials on partial or full clinical hold - MarketWatch
www.marketwatch.com - September 9 at 3:31 AM
fool.com logo5 Things You'll Want to Know From Celgene Corporation's Latest Presentation - Motley Fool
www.fool.com - September 9 at 3:31 AM
finance.yahoo.com logoData Presented at ESMO 2017 Further Evaluate Role of ABRAXANE® for Patients with Historically Challenging Cancers
finance.yahoo.com - September 8 at 5:28 PM
finance.yahoo.com logoData Presented at ESMO 2017 Further Evaluate Role of ABRAXANE® for Patients with Historically Challenging Cancers
finance.yahoo.com - September 8 at 5:28 PM
finance.yahoo.com logoCelgene (CELG) Fusion Program Studies Put on Hold by FDA
finance.yahoo.com - September 8 at 5:28 PM
finance.yahoo.com logoCelgene (CELG) Fusion Program Studies Put on Hold by FDA
finance.yahoo.com - September 8 at 5:28 PM
finance.yahoo.com logoWho Joins Apple On This List Of New Buys By Top Mutual Funds?
finance.yahoo.com - September 8 at 5:28 PM
finance.yahoo.com logoWho Joins Apple On This List Of New Buys By Top Mutual Funds?
finance.yahoo.com - September 8 at 5:28 PM
nasdaq.com logoCelgene Says FDA Places Clinical Hold On FUSION Program
www.nasdaq.com - September 7 at 5:12 PM
nasdaq.com logoCelgene Says FDA Places Clinical Hold On FUSION Program
www.nasdaq.com - September 7 at 5:12 PM
seekingalpha.com logoThoughts On Celgene Rising Despite Negative News Today
seekingalpha.com - September 7 at 5:12 PM
seekingalpha.com logoThoughts On Celgene Rising Despite Negative News Today
seekingalpha.com - September 7 at 5:12 PM
finance.yahoo.com logoCelgene Provides Update on the Fusion™ Clinical Program
finance.yahoo.com - September 7 at 5:12 PM
finance.yahoo.com logoCelgene Provides Update on the Fusion™ Clinical Program
finance.yahoo.com - September 7 at 5:12 PM
finance.yahoo.com logo5 Things You'll Want to Know From Celgene Corporation's Latest Presentation
finance.yahoo.com - September 7 at 5:12 PM
finance.yahoo.com logo5 Things You'll Want to Know From Celgene Corporation's Latest Presentation
finance.yahoo.com - September 7 at 5:12 PM
finance.yahoo.com logoCelgene shares drop 1% on news that FDA has placed six trials on partial or full clinical hold
finance.yahoo.com - September 7 at 5:12 PM
finance.yahoo.com logoCelgene shares drop 1% on news that FDA has placed six trials on partial or full clinical hold
finance.yahoo.com - September 7 at 5:12 PM

Social

Chart

Celgene Corporation (CELG) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff